BioCentury

7:00 AM GMT, Aug 1, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Regulatory

Champix varenicline regulatory update

EMA's CHMP concluded the slightly increased risk of cardiovascular events reported from a meta-analysis of Champix varenicline from Pfizer does not outweigh the benefits of the smoking cessation drug.

Read the full 297 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.